Analysis of vorasidenib-VORANIGO reimbursement conditions and explanations of medical insurance policies and patient fees in different regions

Vorasidenib-VORANIGO is an oral small molecule targeted drug mainly used to treat gliomas with specific IDH1/2 mutations. Since the drug is not currently on the market in China, domestic patients cannot obtain it directly, and it is not included in the national medical insurance reimbursement system. This means that in China, neither urban and rural residents’ medical insurance nor commercial insurance can cover the cost of voxanib, and patients can only rely on overseas channels to obtain it if they need it.

In overseas markets, the original version of voroxiranib is mainly sold in the US version of the original specification of 40mg*30 tablets. Each box is priced at approximately RMB 380,000. The price is relatively high and the financial burden is large for most patients. In addition, generic drugs have been launched overseas, and their drug ingredients are basically the same as the original drugs. Taking the same specification produced by Lucius Pharmaceuticals in Laos as an example, each box sells for about more than 7,000 yuan, which is more accessible to the people than the original drug and provides patients with a feasible choice.

There are obvious differences in medical insurance policies in different regions. In the United States, some commercial insurance or health insurance plans may provide partial reimbursement support to eligible patients, but the specific ratio and approval process vary by state and insurance company. Reimbursement policies vary greatly among European countries. Some countries require strict clinical approval before they can be included in the scope of reimbursement, while in some areas, patients still need to purchase drugs at their own expense. Therefore, patients should fully understand local policies and medical insurance reimbursement conditions before planning to use vorsidenib.
In terms of clinical recommendations, vorsidenib, as a targeted drug, should be used in patients with clear IDH1/2 mutation positivity to ensure efficacy and safety. When patients purchase drugs overseas, they should ensure drug quality through formal channels and pay attention to transportation and storage conditions. In addition, regular follow-up and monitoring of hematological indicators and liver and kidney functions are required during use, and dosage adjustments should be made based on the guidance of professional doctors to ensure the therapeutic effect and reduce the risk of adverse reactions.
Keyword tag:
IDH1/2 inhibitors, glioma, targeted therapy, oral drugs, side effect management, treatment course evaluation, regular drug purchase channels, drug prices
Reference: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vorasidenib-grade-2-astrocytoma-or-oligodendroglioma-susceptible-idh1-or-idh2-mutation